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Abstract
Hepatocyte growth factor/scatter factor (HGF/SF) can induce proliferation and motility and promote invasion of tumor cells. Since HGF/
SF receptor, c-Met, is expressed by tumor cells, and since stimulation of CD44, a transmembrane glycoprotein known to bind hyaluronic acid
(HA) in its extracellular domain, is involved in activation of c-Met, we have studied the effects of CD44 stimulation by ligation with HA
upon the expression and tyrosine phosphorylation of c-Met on human chondrosarcoma cell line HCS-2/8. The current study indicates that (a)
CD44 stimulation by fragmented HA upregulates expression of c-Met proteins; (b) fragmented HA also induces tyrosine phosphorylation of
c-Met protein within 30 min, an early event in this pathway as shown by the early time course of stimulation; (c) the effects of HA fragments
are critically HA size-dependent. High molecular weight HA is inactive, but lower molecular weight fragments (Mr 3.5 kDa) are active with
maximal effect in the Ag/ml range; (d) the standard form of CD44 (CD44s) is critical for the response because the effect on c-Met, both in
terms of upregulation and phosphorylation, is inhibited by preincubation with an anti-CD44 monoclonal antibody; and (e) phosphorylation of
c-Met induced by CD44 stimulation is inhibited by protein tyrosine kinase inhibitor, tyrphostin. Therefore, our study represents the first
report that CD44 stimulation induced by fragmented HA enhances c-Met expression and tyrosine phosphorylation in human chondrosarcoma
cells. Taken together, these studies establish a signal transduction cascade or cross-talk emanating from CD44 to c-Met.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The cellular functions are dependent upon a number of
cell surface adhesion proteins and CD44 has been impli-
cated as one such molecule [1,2]. CD44 is a transmembrane
glycoprotein known to bind hyaluronic acid (HA) in its
extracellular domain [3]. CD44 is known to exist in many
different isoforms arising by alternative splicing events [4].
HA is a nonsulfated, linear glycosaminoglycan consisting of
repeating units of (h,1-4)-D-glucuronic acid-(h,1-3)-N-
acethyl-D-glucosamine [5]. Several studies have suggested
that high and low molecular weight species of HA exhibit
different biological effects on cells [6,7]. Low molecular
weight, but not native, HA has been shown to stimulate the
expression of cytokines, proinflammatory chemokines and
cell adhesion molecules possibly through a mechanism
involving the cellular HA receptor, CD44 [8–15].
In common with other cell surface molecules, there is
evidence that ligand binding may be enhanced by the
multimerization of CD44 [16]. It is now apparent that
CD44 interacts with the HER2 (p185, c-ErbB2) cell surface
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tyrosine kinase protein. HA binding stimulates HER2 tyro-
sine kinase activity, leading to an increase in tumor cell
growth [17]. The cytoplasmic domain of CD44 has been
shown to bind directly to a number of intracellular proteins,
including ankyrin [18,19], ERM family [20] and protein 4.1
[21]. These proteins connect elements of the plasma mem-
brane with the actin filament network of the cell and thus a
direct link between CD44 and intracellular scaffold struc-
tures can be envisioned, facilitating cell motility and migra-
tion [22].
It has also been reported that, although precise mecha-
nisms are not known, CD44 stimulation is involved in
activation of c-Met, which is a specific receptor for hep-
atocyte growth factor/scatter factor (HGF/SF) [23]. HGF/SF
can induce proliferation and motility in epithelial cells and
promotes invasion of tumor cells [24–26]. It also stimulates
upregulation of urokinase-type plasminogen activator (uPA)
in tumor cells [27,28], which is considered to be a bio-
marker of tumor invasion. Furthermore, it has been estab-
lished that stimulation of endothelial monolayers with HGF/
SF resulted in an upregulation of CD44 expression together
with enhancement of tumor cell–endothelial cell adherence
and this factor may act to facilitate metastatic spread
[29,30]. Thus, HGF/SF plays a key role in the initial
adhesion mechanism between tumor cells and endothelial
cells via upregulation of CD44. A recent study by Kawa-
kami-Kimura et al. [31] has shown that HGF/SF upregulates
the expression of tumor cell integrin molecules, resulting in
enhancement of their adhesive properties towards extracel-
lular matrix (ECM) components. HGF/SF upregulates the
production of not only uPA but also matrix metalloprotei-
nases (MMP) [32]. These observations further implicate
HGF/SF in the enhancement of tumor cell interactions
necessary for successful metastasis. These data allow us to
hypothesize that there is a cross-talk between CD44 and c-
Met system.
In the present study, we have studied the effects of CD44
stimulation by ligation with HA upon the expression and
tyrosine phosphorylation of c-Met in human chondrosar-
coma cell line HCS-2/8.
2. Materials and methods
2.1. Chemicals and reagents
Purified native HA and HA fragments (kindly provided
by Dr. M. Ikeda, Seikagaku Kogyo Co. Ltd., Tokyo, Japan)
were derived from rooster comb and had an average
molecular weight of 2200, 1000, 640, 350 and 3.5 kDa.
These HA preparations are free of protein ( < 2%) and free
of chondroitin sulfate ( < 3%). Anti-CD44 monoclonal anti-
body (mAb), chondroitin-4-sulfate, chondroitin-6-sulfate,
dermatan sulfate, keratan sulfate and heparan sulfate were
also from Seikagaku Kogyo. Fetal calf serum (FCS) was
obtained from Life Technologies (Rockville, MD). Anti-
CD44 mAb specifically inhibits HA binding to CD44. The
ECL enhanced chemiluminescence detection kit was pur-
chased from Amersham Japan (Tokyo). PY20 antiphspho-
tyrosine mAb was from Zymed (South San Francisco, CA,
USA). Anti-c-Met rabbit polyclonal antibody (pAb) was
from Santa Cruz Biotechnology, CA, USA (an affinity-
purified polyclonal rabbit IgG raised against the synthetic
peptide corresponding to the 28 C-terminal amino acids of
the human c-Met protein). Protein A/G-agarose beads and
tyrphostin A25 were from Calbiochem (Cambridge, MA).
2.2. Cells and culture conditions
Human chondrosarcoma cell line HCS-2/8 was grown
and cultured as previously described [33]. Briefly, the HCS-
2/8 cells were harvested and aliquoted into tissue culture
plates (2 106 cells/well) in Dulbecco’s minimum essential
medium with Eagle’s Salts (DMEM) supplemented with
penicillin (100 U/ml), streptomycin (100 Ag/ml) and 10%
heat-inactivated FCS. On the next day, the cells were
washed three times with phosphate-buffered saline (PBS)
to remove serum, and the medium was replaced with
DMEM supplemented with antibiotics. Serum-free medium
plus the test drugs were added and incubation was continued
for different time lapses. After culture, medium was aspi-
rated and cells were harvested and washed extensively.
In a parallel experiment, serum-starved HCS-2/8 cells
were preincubated without or with different concentrations
(0–50 AM) of tyrphostin for 4 h in DMEM and subse-
quently stimulated with fragmented HA.
2.3. Western blot and immunoprecipitation to detect c-Met
protein
Serum-starved cells were treated for different periods of
time with high molecular weight and fragmented HA (0–
1000 Ag/ml). Cells were washed three times with PBS, and
the cell membrane proteins were solubilized at 4 jC for 16 h
with 1 ml of lysis buffer [0.5% Nonidet P-40 and 0.02%
sodium azide in PBS containing 1 mM phenylmethylsul-
fonyl fluoride (PMSF)]. The solubilized cell preparation was
processed by centrifugation at 8000 g for 5 min, and the
supernatant (50 Ag of protein) was boiled for 5 min in
nonreducing sample buffer and resolved in a 10% gel.
Protein determinations were performed using the BCA
protein assay [34]. Western blot was performed with poly-
vinylidine difluoride (PVDF) membrane using a transblot
system (Marisol, Tokyo). The protein bands were then
revealed using the ECL detection system (Amersham Japan)
according to the manufacturer’s protocol. Anti-c-Met pAb
or anti-CD44s mAb was used at a final concentration of 0.5
Ag/ml. Protein molecular weight standards were run simul-
taneously on the gels.
Total protein (200 Ag) from each specimen was used for
immunoprecipitation. Protein A/G-agarose beads (20 Al) and
2 Ag of nonimmune IgG were added to each protein sample.
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The reaction mixture was incubated for 2 h at 4 jC in a shaker
and centrifuged at 8000 g for 5 min. The supernatant was
combined with 1 Ag of anti-c-Met pAb or nonimmune rabbit
IgG. Protein A/G-agarose beads (20 Al) were added, and the
mixture was incubated in a shaker for an additional 2 h at 4
jC. The mixture was again centrifuged at 8000 g for 5 min.
The pellet was washed four times with 100 mM Tris–HCl,
pH 7.4, 150 mMNaCl, 1 mM PMSF, 1 mM sodium vanadate
with 2 Ag/ml aprotinin, 2 Ag/ml leupeptin and 0.1% Triton X-
100. The pellet was resuspended in 2 sample buffer, boiled
for 10 min, centrifuged at 8000 g, and 20 Al of sample was
loaded on an SDS–10% polyacrylamide gel under nonreduc-
ing conditions. Immunoblot was performed as described
above. The membranes were blocked with 2% bovine serum
albumin (BSA), and tyrosine-phosphorylated proteins were
immunodetected by incubating the blots with anti-phospho-
tyrosine PY-20 mAb at a final concentration of 0.5 Ag/ml.
Protein molecular weight standards were run simultaneously
on the gels.
3. Results
3.1. Involvement of CD44 in the upregulation of c-Met
protein by fragmented HA
When a human chondrosarcoma cell line HCS-2/8 was
probed for expression of CD44 with anti-CD44 antibody,
cells were positive for the standard form of CD44 (CD44s)
expression as indicated by a band detected at 85 kDa by
Western blot (Fig. 1). In a parallel experiment, we also
assessed the expression of CD44 protein on HCS-2/8 cells
using flow cytometry. The CD44 was highly and consis-
tently expressed on cells (data not shown). To characterize
whether the 85-kDa CD44s is functionally active, we first
investigated the ability of fragmented HA to induce expres-
sion of c-Met protein in HCS-2/8 cells. We confirmed in the
present study that HA, especially when fragmented, is a
possible ligand involved in CD44-mediated expression of c-
Met protein (see below).
Fig. 2 shows that treatment of HCS-2/8 cells with
fragmented HA, at a peak molecular mass of 3.5 kDa,
upregulates c-Met protein, as evidenced by immunoblotting.
A pAb against the C-terminal region of human c-Met
receptor protein, whose specificity for detecting the mature
and the precursor forms of the c-Met receptor is well
characterized, was used. We detected two forms of immu-
noreactive c-Met, corresponding to a 170-kDa precursor
form and a h chain of Mr 145 kDa. The 170-kDa precursor
c-Met represents the newly synthesized and unprocessed
form. The mature protein (p190), under reducing conditions,
gives rise to an a chain ofMr 50 kDa and a h chain ofMr 145
kDa. Both the 70- and 50-kDa bands seem to represent
nonspecific forms, since anti-c-Met antibody used in this
study does not recognize the a chain ofMr 50 kDa, and since
the intensity of both the 70- and 50-kDa bands does not
change during the entire period. Fig. 2A shows a time course
of upregulation of c-Met, the effect being evident from 6 h
and peaking at 24 h. The c-Met upregulation was still
detectable after 48 h. Furthermore, the effect of fragmented
HA on the c-Met protein upregulation was dose-dependent
over the dose range of 3.1–50 Ag/ml as shown in Fig. 2B.
We investigated directly the role of CD44s in mediating
HA stimulation of c-Met protein. When HCS-2/8 cells were
preincubated with anti-CD44 mAb, which has been shown
to block the binding of HA, the Mr 3.5 kDa fragmented HA-
induced upregulation of c-Met protein was significantly
reduced (Fig. 3). However, fragmented HA-induced c-Met
protein upregulation was unaffected by preincubation with
nonimmune mouse IgG. These data clearly establish that
CD44s plays an important role in mediating the effects of
fragmented HA on upregulation of c-Met protein.
3.2. The effect of HA size and concentration in the
upregulation of c-Met protein
We asked whether the upregulation of c-Met protein is
dependent on HA size. The HCS-2/8 cells were first
exposed for 12 h to HA with different molecular masses
[Mr 2200 kDa (1 mg/ml), Mr 1000 kDa (500 Ag/ml), Mr 640
kDa (320 Ag/ml), Mr 350 kDa (175 Ag/ml) or Mr 3.5 kDa
Fig. 1. Expression of CD44 protein in HCS-2/8 cells. Solubilized cell
preparations (50 Ag/lane) from HCS-2/8 cells were probed for CD44
immunoreactivity using a monoclonal anti-CD44 antibody (lane 1) or
nonimmune mouse IgG (lane 2). Only one band of 85 kDa was detected and
corresponded to standard form of CD44 (CD44s). Results are representative
of two separate experiments.
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(1.8 Ag/ml)]. Fig. 4A demonstrates that expression of c-Met
protein was significantly induced only by the addition of the
Mr 3.5 kDa fragment of HA [1.8 Ag/ml ( =f 0.5 AM)]. In
contrast, other HA compounds (Mr 350, 640, 1000 and 2200
kDa) (all f 0.5 AM) failed to induce the upregulation of c-
Met protein. Further, we treated cells with the different HA
sizes at different concentrations, and c-Met proteins were
visualized in Western blots using anti-c-Met antibody. Fig.
4B demonstrates that the stimulatory activity of the 3.5-kDa
HA fragments was dose-dependent, with maximal effect in
the Ag/ml range. The effect of the 3.5-kDa HA fragments is
observed at a concentration as low as 1.0 Ag/ml. The higher-
molecular-mass forms of HA (from 350 to 2200 kDa) were
unable to induce the c-Met expression also when used at any
concentration used (up to 1000 Ag/ml).
Related glycosaminoglycans, including chondroitin-4-
sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sul-
fate and heparan sulfate, all failed to induce the expression
of c-Met protein in HCS-2/8 cells (data not shown). These
data suggest that HA, especially when fragmented, is a
possible ligand involved in CD44-mediated expression of c-
Met protein. Therefore, this effect was markedly dependent
on the molecular weight and concentration of the HA.
3.3. Effect of CD44 stimulation by fragmented HA on
tyrosine phosphorylation of c-Met protein
We next examined the effect of CD44 stimulation by HA
compounds on tyrosine phosphorylation of c-Met protein, a
critical event in the activation of this receptor. HCS-2/8 cells
treated with HA with different molecular masses were
examined for phosphorylation of c-Met protein. The cell
lysate from HCS-2/8 treated with high-molecular-mass
forms of HA or fragmented HA was subjected to immuno-
precipitation with anti-c-Met pAb, and then immunoblotted
Fig. 3. Fragmented HA induces c-Met upregulation via CD44. Serum-
starved HCS-2/8 cells were preincubated with anti-CD44 mAb (50 Ag/ml;
lane 1) or nonimmune mouse IgG (NI-IgG; 50 Ag/ml; lane 2) for 1 h
before stimulation with the Mr 3.5 kDa fragmented HA (1.8 Ag/ml) for 12
h. The cell lysates (50 Ag/lane) were prepared from HCS-2/8 cells and
assessed for expression of c-Met protein. Data are representative of two
separate experiments.
Fig. 2. Fragmented HA induces upregulation of c-Met receptor protein in
HCS-2/8 cells in a time- and dose-dependent manner. (A) Serum-starved
HCS-2/8 cells were treated with the Mr 3.5 kDa fragmented HA (1.8 Ag/ml)
from 0 to 48 h as indicated. (B) Cells were treated with fragmented HA
from 0.2 to 200 Ag/ml for 12 h. The cells were lyzed by the addition of lysis
buffer. Total protein (50 Ag) was subjected to 10% SDS-PAGE and
analyzed with Western blot using commercially available antihuman c-Met
pAb. The 170- and 145-kDa protein bands corresponding to intact c-Met
receptor and h-subunit of c-Met protein, respectively, were recognized in
solubilized preparations by the c-Met pAb. The control nonimmune rabbit
IgG did not recognize these bands. Nonspecific bands (70 and 50 kDa) are
presented to show the equal loading of each sample. Results are
representative of two separate experiments.
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using anti-phosphotyrosine mAb (Fig. 5). Exposure of the
cells to the 3.5-kDa fragmented HA caused a time-depend-
ent increase in phosphorylation of c-Met protein (Fig. 5A).
Tyrosine phosphorylation of c-Met was most pronounced at
30 min after CD44 stimulation. Furthermore, the effect of
fragmented HA on c-Met phosphorylation was dependent
on concentrations of fragmented HA (Fig. 5B). Maximal
induction of c-Met phosphorylation was observed with 3.1–
12.5 Ag/ml fragmented HA in two separate experiments.
The relationship between CD44 stimulation and c-Met
phosphorylation was further determined by application of
a specific inhibitor of tyrosine phosphorylation, tyrphostin.
As expected, tyrphostin dose-dependently inhibited the
fragmented HA-induced c-Met phosphorylation; f 70%
Fig. 5. Effect of CD44 stimulation by fragmented HA on tyrosine
phosphorylation of c-Met protein. (A) Serum-starved HCS-2/8 cells were
left untreated or treated with the 3.5-kDa fragmented HA for different
periods of time in the absence or presence of tyrophostin (25 AM). (B)
HCS-2/8 cells were left untreated or treated with different concentrations
(0.2–200 Ag/ml) of the 3.5-kDa fragmented HA for 30 min in the absence
or presence of tyrphostin (25 AM). Cell lysates (50 Ag/lane) were
immunoprecipitated with anti-c-Met pAb followed by immunoblotted
using anti-phosphotyrosine antibody. Specific phospho c-Met bands of 170
and 145 kDa were detected. No other protein bands except those shown
were observed. Data are representative of two separate experiments.
Fig. 4. HA fragment induced upregulation of c-Met protein is size- and
concentration-dependent. (A) Serum-starved HCS-2/8 were treated with
medium alone ( ) or HA with different molecular mass [Mr 3.5 kDa (1.8
Ag/ml), Mr 350 kDa (175 Ag/ml), Mr 640 kDa (320 Ag/ml), Mr 1000 kDa
(500 Ag/ml) or Mr 2200 kDa (1 mg/ml)] for 12 h. (B) Cells were treated
with the different HA sizes at different concentrations for 12 h. Cell extracts
(50 Ag/lane) were prepared and assessed for c-Met expression by Western
blot. Results shown are representative of two separate experiments.
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at 25 AM and f 90% at 50 AM (data not shown). In a
parallel experiment, the effect on c-Met, in terms of tyrosine
phosphorylation, is also inhibited by preincubation with
anti-CD44 mAb (data not shown). Again, the high-molec-
ular-mass forms of HA failed to stimulate the phosphoryla-
tion of the c-Met proteins (data not shown).
4. Discussion
The main findings of the present study were the follow-
ing: (a) the standard form of CD44 (CD44s) is expressed on
HCS-2/8 cells; (b) CD44 stimulation by fragmented HA
upregulates expression of c-Met protein. Upregulation of c-
Met receptor protein after CD44 stimulation takes several
hours; (c) HA fragments induce tyrosine phosphorylation of
c-Met protein, an early event in this pathway as shown by
the early time course of stimulation; (d) the effect of HA
fragments is critically HA-size-dependent. High-molecular-
mass HA (from 350 to 2200 kDa) is inactive, but lower
molecular mass fragmented HA (Mr 3.5 kDa) is active; (e)
the stimulatory activity of the 3.5-kDa HA fragments was
dose-dependent, with maximal effect in the Ag/ml range,
whereas the higher-molecular-mass forms of HA ( > 350
kDa) were unable to induce the c-Met expression at any
concentration used (up to 1000 Ag/ml); (f) the effect on c-
Met, both in terms of upregulation and phosphorylation, is
inhibited by preincubation with the anti-CD44 mAb, which
has been shown to inhibit HA binding to the CD44; and (g)
upregulation and phosphorylation of c-Met induced by
CD44 stimulation is inhibited by protein tyrosine kinase
inhibitor, tyrphostin. Therefore, a role for CD44 in frag-
mented HA-induced upregulation and phosphorylation of c-
Met receptor is clearly indicated in human chondrosarcoma
cell line HCS-2/8.
HA has been shown to influence several aspects of cell
behavior (proliferation, differentiation, migration and adhe-
sion), but its effect greatly depends on at least three
parameters: the size and concentration of the HA and the
type of cells. It has been reported that the effects of HA are
sometimes multivalent: higher-molecular-weights of HA are
inhibitory at high concentration but stimulatory at low
concentrations, e.g. its effect on cell proliferation [35].
Therefore, a wide range of concentrations were tested at
each molecular weight to determine whether this is really an
effect of ‘‘’fragments’’ or of size vs. concentration. Here, we
report that the 3.5-kDa HA fragments specifically induced
the expression of c-Met in a dose–response manner with
maximal effect in the Ag/ml range, while the higher-molec-
ular-mass forms of HA (from 350 to 2200 kDa) were
ineffective.
In the Western blot/immunoprecipitation procedures, the
anti-c-Met pAb specifically recognizes the protein bands
corresponding to intact 170 kDa and h subunit 145 kDa
proteins. Since the pAb was raised against the synthetic
peptide corresponding to the C-terminal amino acids of the
human c-Met receptor protein, the reactivity with both the
intact and b subunit of the c-Met receptor was expected.
However, we used nonreducing conditions that should not
dissociate the disulfide-linked 145-kDa h subunit from the
50-kDa a subunit. Our results are in agreement with the data
reported by Herness and Naz [36], in which they reported
that the c-Met receptor protein is present both as an intact as
well as an isolated h subunit.
Our study represents the first report that CD44 stimulation
induced by fragmented HA enhances c-Met upregulation and
tyrosine phosphorylation in human chondrosarcoma cells.
The effect of fragmented HA on the tyrosine phosphoryla-
tion was rapid and was seen as early as 30 min after
stimulation. It is likely that a conformational change of
CD44 is induced that allows interaction with fragmented
HA to occur within minutes [37] for induction of tyrosine
phosphorylation of c-Met receptor itself. In contrast, upre-
gulation of c-Met receptor protein after fragmented HA
binding takes several hours and may be accompanied by
de novo synthesis of c-Met receptor.
It has been recently recognized that CD44 functions as a
signaling receptor in a variety of cell types. Cell stimulation
by anti-CD44 antibodies or natural CD44 ligands activate
several signaling pathways that culminate in cell prolifera-
tion, cytokine secretion, chemokine gene expression and
cytolytic effector functions [38]. There are some mecha-
nisms whereby CD44 assembles the signaling machinery
required for activation of c-Met receptor. One of the earliest
signaling events following stimulation via CD44 is tyrosine
phosphorylation of intracellular protein substrates. A large
body of evidence has accumulated that stimulation via CD44
using antibody or HA fragments increases tyrosine phos-
phorylation of intracellular protein substrates [39–43]. Since
CD44 lacks an intrinsic protein tyrosine kinase activity,
increased tyrosine phosphorylation could only arise from
direct or indirect interaction with c-Met. It is possible that
there is a functional cross-talk between CD44 and c-Met.
CD44 physically and functionally interacts with the Src-
family protein tyrosine kinases, which are involved in c-Met
signaling [44,45]. Also, ezrin may be involved in intra-
cellular cross-talk between CD44 and c-Met. Ezrin binds
directly to the cytoplasmic domain of CD44 and to the actin
cytoskeleton [19,20]. Furthermore, ezrin is a substrate for c-
Met shown to be involved in HGF/SF-induced cell migration
[46]. Thus, CD44 may promote c-Met signaling by an
intracellular mechanism.
It has been clearly shown that partial degradation prod-
ucts of HA had an angiogenic potential that was lacking in
macromolecular HA [47] and that the cell-stimulatory
effects of HA–CD44 interaction are indeed mediated by
smaller HA fragments that stimulated macrophages to
secrete the proinflammatory cytokines [8–15]. Our results
are in agreement with that observed for induction of proin-
flammatory gene expression by HA fragments [8–15]. The
basis for the difference between HA fragments and native
HA is unclear. One possible explanation for the failure of
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high-molecular-mass HA to activate c-Met receptor is that
the high-molecular-mass forms may bind to cells in such a
way as to prevent receptor cross-linking or dimerization.
These evidences allow us to hypothesize that stimulation by
CD44 ligation with fragmented HA induces outside-in
signaling, which may augment phosphorylation and upre-
gulation of c-Met by intracellular signal transduction or
inside-out signaling. This plays a pivotal role in the HA-
mediated adhesion of cells and subsequent invasion and
metastasis.
The significance of this discovery is heightened by the
fact that c-Met protein tyrosine phosphorylation is capable
of inducing upregulation of uPA [32]. This has been
identified as a potent proteinase digesting ECM compo-
nents. It has also been reported that uPA participates in the
membrane-associated activation process of MMP. Upregu-
lated uPA and MMP has been observed in a number of
aggressive tumor cells [48–52]. Preliminary data from our
laboratory (M. Suzuki and H. Kobayashi; unpublished data,
2001) showed that CD44 stimulation promotes HCS-2/8 cell
invasion and that phosphorylation and overexpression of
surface c-Met in fragmented HA-treated cells result in a
dramatic enhancement of uPA expression. Thus, the upre-
gulation in HCS-2/8 cell invasion seen in response to CD44
stimulation involved, at least in part, the uPA–MMP fibri-
nolytic system. These data allow us to hypothesize that
CD44 stimulation plays a key role in the invasion of HCS-2/
8 cells via upregulation of uPA through c-Met-dependent
activation mechanism.
In summary, the present study reveals a novel function of
CD44 stimulation by fragmented HA in HCS-2/8 cells,
including c-Met upregulation and activation, which further
supports the role of c-Met as an invasion-promoting factor.
These findings expand our understanding of the role of CD44
in tumor cell adhesion and activation that can in turn stimulate
tumor cell invasion. Among tumor cells expressing autocrine
loop (CD44 stimulation! c-Met activation! uPA/MMP
overexpression), there may be a significant correlation
between the magnitude of CD44 stimulation and invasive-
ness. Identification of CD44-dependent c-Met induction and
c-Met-dependent uPA/MMP induction as well as reagents
capable of inhibiting these processes may prove useful in
retarding tumor metastasis. We are now examining in detail
the signal transduction pathway activated by HA fragments
leading to c-Met upregulation and phosphorylation using
HCS-2/8 cells as a model system.
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